Published in J Clin Microbiol on March 01, 1996
The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin Infect Dis (2010) 5.34
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother (1999) 1.99
Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (2000) 1.69
Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother (2001) 1.38
Community acquired infections and bacterial resistance. BMJ (1998) 1.32
Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections. J Clin Microbiol (1997) 1.19
A nosocomial outbreak due to Enterobacter cloacae strains with the E. hormaechei genotype in patients treated with fluoroquinolones. J Clin Microbiol (1997) 1.13
Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol (2001) 1.08
In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob Agents Chemother (2000) 1.01
In vitro activities of cephalosporins and quinolones against Escherichia coli strains isolated from diarrheic dairy calves. Antimicrob Agents Chemother (1999) 0.88
Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions. Infect Control Hosp Epidemiol (2012) 0.75
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother (1994) 6.39
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis (1984) 4.42
Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother (1993) 3.86
Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis (1991) 3.12
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother (1994) 2.87
Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1993) 2.68
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother (1994) 2.24
Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother (1991) 1.87
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med (1994) 1.81
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother (1987) 1.62
Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance. Am J Med (1989) 1.60
Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis (1994) 1.60
Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob Agents Chemother (1991) 1.52
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother (1994) 1.49
Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency. J Antimicrob Chemother (1990) 1.45
Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection (1994) 1.31
Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis (1993) 1.30
Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis (1994) 1.29
Mode of action of the new quinolones: new data. Eur J Clin Microbiol Infect Dis (1991) 1.27
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother (1994) 1.23
Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains. J Antimicrob Chemother (1991) 1.18
Escherichia coli in fecal flora of healthy adults: serotypes, P and type 1C fimbriae, non-P mannose-resistant adhesins, and hemolytic activity. J Infect Dis (1992) 1.14
Mechanisms of quinolone resistance. Infection (1994) 1.13
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. Diagn Microbiol Infect Dis (1994) 1.02
Fleroxacin resistance in Escherichia coli. Antimicrob Agents Chemother (1989) 0.97
Multiclonal emergence of ciprofloxacin-resistant clinical isolates of Escherichia coli and Klebsiella pneumoniae. J Antimicrob Chemother (1994) 0.97
Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob Agents Chemother (1993) 0.97
First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia. Eur J Clin Microbiol Infect Dis (1990) 0.90
Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain. Eur J Clin Microbiol Infect Dis (1993) 0.89
Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. Eur J Clin Microbiol Infect Dis (1990) 0.86
Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis (1994) 0.85
Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infection (1994) 0.81
Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli. J Antimicrob Chemother (1994) 0.78
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol (1981) 4.31
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol (2001) 4.13
A neuronal learning rule for sub-millisecond temporal coding. Nature (1996) 3.76
Retrovirus genomes methylated by mammalian but not bacterial methylase are non-infectious. Nature (1983) 3.43
Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med (1977) 3.38
Synergy during in vitro cytotoxic allograft responses. I. Evidence for cell interaction between thymocytes and peripheral T cells. J Exp Med (1973) 3.24
Neural basis of alertness and cognitive performance impairments during sleepiness. I. Effects of 24 h of sleep deprivation on waking human regional brain activity. J Sleep Res (2000) 3.17
Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem (2001) 3.16
Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol (1998) 3.11
CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 3.06
Virus and trinitrophenol hapten-specific T-cell-mediated cytotoxicity against H-2 incompatible target cells. J Exp Med (1976) 3.00
Baseline findings in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. Invest Ophthalmol Vis Sci (1998) 2.68
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature (1980) 2.39
CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 2.31
[Surgical leg prolongation]. Chirurg (1971) 2.28
Primary responses of human T cells to mycobacteria: a frequent set of gamma/delta T cells are stimulated by protease-resistant ligands. Eur J Immunol (1990) 2.25
Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol (2001) 2.24
Bacterial DNA causes septic shock. Nature (1997) 2.19
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15
Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol (1997) 2.10
Induction of cytotoxic T lymphocytes against I-region-coded determinants: in vitro evidence for a third histocompatibility locus in the mouse. J Exp Med (1975) 2.09
A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. Eur J Immunol (1991) 2.06
Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol (1994) 2.04
Perception and neuronal coding of subjective contours in the owl. Nat Neurosci (1999) 2.01
(+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.99
Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89
The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes. J Immunol (1977) 1.86
Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol (2003) 1.86
Operative lengthening of the femur. Clin Orthop Relat Res (1978) 1.81
CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol (1997) 1.79
T-T cell interactions during cytotoxic T lymphocyte (CTL) responses: T cell derived helper factor (Interleukin 2) as a probe to analyze CTL responsiveness and thymic maturation of CTL progenitors. Immunol Rev (1980) 1.78
[Possibilities and experiences with cartilage transplantation]. Z Orthop Ihre Grenzgeb (1972) 1.78
Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. Am J Physiol (1999) 1.78
The Caregiver Quality of Life Index-Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer. Qual Life Res (1999) 1.76
Neural encoding of binocular disparity: energy models, position shifts and phase shifts. Vision Res (1996) 1.74
T-cell-mediated immune responses induced in vitro: a probe for allograft and tumor immunity. Transplant Rev (1973) 1.74
IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol (2001) 1.73
Cell-mediated immune response in vitro. I. A new in vitro system for the generation of cell-mediated cytotoxic activity. Cell Immunol (1972) 1.67
Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun (1998) 1.64
Surface replacement arthroplasty of the hip. Clin Orthop Relat Res (1979) 1.63
T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells. Nature (1977) 1.61
Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. J Exp Med (1981) 1.59
Angiogenic growth factor mRNA responses in muscle to a single bout of exercise. J Appl Physiol (1985) (1996) 1.59
Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ (2004) 1.59
Antiinflammatory sydnones. 1. J Med Chem (1974) 1.59
Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol (2000) 1.58
T cell proliferation in the mixed lymphocyte culture does not necessarily result in the generation of cytotoxic T effector cells. Eur J Immunol (1975) 1.56
Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg (1999) 1.56
Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol (1997) 1.56
Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J (1999) 1.56
Structural analysis of an RNA molecule involved in replication control of plasmid R1. Nucleic Acids Res (1986) 1.55
Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol (1993) 1.54
The correlation between the proliferative and the cytotoxic responses of mouse lymphocytes to allogeneic cells in vitro. J Immunol (1972) 1.54
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood (2000) 1.51
Effect of prolonged, heavy exercise on pulmonary gas exchange in athletes. J Appl Physiol (1985) (1998) 1.51
Listeriosis in p47(phox-/-) and TRp55-/- mice: protection despite absence of ROI and susceptibility despite presence of RNI. Immunity (1997) 1.50
Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg (2000) 1.50
Interleukin 2 induction in Lyt 1+ 23- T cells from Listeria monocytogenes-immune mice. Infect Immun (1982) 1.49
[Total joint surfact replacement in the hip joint. Preliminary communication]. Arch Orthop Unfallchir (1975) 1.47
CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol (1999) 1.46
Aneurysm of the membranous ventricular septum. Surgical consideration and experience in 29 cases. J Thorac Cardiovasc Surg (1976) 1.46
Immunomodulation by intravenous immunoglobulin. Am J Pediatr Hematol Oncol (1990) 1.46
[Stimulation interval-dependent acoustic evoked potentials]. Acta Otolaryngol (1974) 1.44
Frequency of herpes simplex virus-specific murine cytotoxic T lymphocyte precursors in mitogen- and antigen-driven primary in vitro T cell responses. J Immunol (1987) 1.44
Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun (1997) 1.44
Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol (2002) 1.42
Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol (2001) 1.41
Complete DNA methylation does not prevent polyoma and simian virus 40 virus early gene expression. Proc Natl Acad Sci U S A (1983) 1.39
Integration of foreign sequences into the tobacco plastome via polyethylene glycol-mediated protoplast transformation. Planta (1996) 1.39
Plasmodium falciparum merozoites primarily stimulate the V gamma 9 subset of human gamma/delta T cells. Eur J Immunol (1991) 1.34
A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J Immunol Methods (1985) 1.33
Failure of an automated blood culture system to detect nonfermentative gram-negative bacteria. J Clin Microbiol (2000) 1.33
Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol (1997) 1.31
Impact of thymus on the generation of immunocompetence and diversity of antigen-specific MHC-restricted cytotoxic T-lymphocyte precursors. Immunol Rev (1981) 1.31
Superantigen mediated shock: a cytokine release syndrome. Immunobiology (1993) 1.29
In vitro induction of tumor specific immunity: requirements for T lymphocytes and tumor growth inhibition in vivo. Eur J Immunol (1973) 1.29
Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering. J Immunol (1986) 1.27
Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation. Phytomedicine (1999) 1.27
Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol (2000) 1.26
Humoral and cell mediated responses in vitro of spleen cells from mice with thymic aplasia (nude mice). Aust J Exp Biol Med Sci (1972) 1.26
Exercise adaptation attenuates VEGF gene expression in human skeletal muscle. Am J Physiol Heart Circ Physiol (2000) 1.26
Critical review and meta-analysis of serial agitated dilutions in experimental toxicology. Hum Exp Toxicol (1994) 1.26
Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. J Natl Cancer Inst (1989) 1.26
Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol (1999) 1.25
Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol (1993) 1.24
DNA activates human immune cells through a CpG sequence-dependent manner. Immunology (1999) 1.23
Intrathymic differentiation of cytotoxic T lymphocyte (CTL) precursors. I. The CTL immunocompetence of peanut agglutinin-positive (cortical) and negative (medullary) Lyt 123 thymocytes. J Immunol (1980) 1.23
Fatal anthrax infection in a heroin user from southern Germany, June 2012. Euro Surveill (2012) 1.23
Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase. J Biol Chem (1996) 1.22